**Response to antenatal cholecalciferol supplementation is associated with common vitamin D related genetic variants**

Rebecca J Moon1,2\*, Nicholas C Harvey1,3\*, Cyrus Cooper1,3,4\*,Stefania D’Angelo1, Elizabeth M Curtis1, Sarah R Crozier1, Sheila J. Barton1, Sian M Robinson1,3, Keith M Godfrey1,3, Nikki J Graham5, John W Holloway5, Nicholas J Bishop6, Stephen Kennedy7, Aris T Papageorghiou7, Inez Schoenmakers8,9, Robert Fraser10, Saurabh V Gandhi10, Ann Prentice8, Hazel M Inskip1,3, M Kassim Javaid4 and the MAVIDOS Trial Group

1. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

2. Paediatric Endocrinology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK

3. NIHR Southampton Nutrition Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

4. National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, UK

5. Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK

6. Academic Unit of Child Health, Sheffield Children’s Hospital, University of Sheffield, Sheffield, UK

7. Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, University of Oxford, Oxford, UK

8. MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, UK

9. Department of Medicine, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

10. Sheffield Hospitals NHS Trust (University of Sheffield), Sheffield, UK

\*RJM, NCH and CC are joint first authors

MAVIDOS Trial Group: Nigel K Arden, Andrew Carr, Elaine M Dennison, Richard Eastell, M Zulf Mughal, David M Reid

**Short title:** Response to antenatal vitamin D: genetic factors

**Key words**: 25-hydroxyvitamin D; single nucleotide polymorphism; DHCR7; CYP2R1; GC; pregnancy; cholecalciferol

**Corresponding Author and person to whom reprint requests should be addressed:**

Professor Cyrus Cooper,

MRC Lifecourse Epidemiology Unit,

University of Southampton,

Southampton General Hospital,

Southampton.

SO16 6YD

Tel: 023 8077 7624

Fax: 023 8070 4021

Email: cc@mrc.soton.ac.uk

**Sources of Support:**

This work was supported by grants from the Arthritis Research UK (17702), Medical Research Council (4050502589), Bupa Foundation, National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, and NIHR Musculoskeletal Biomedical Research Unit, University of Oxford. IS and AP were funded by the Medical Research Council (MRC) (programme code U105960371). The work leading to these results was supported by the European Union's Seventh Framework Programme (FP7/2007-2013), projects EarlyNutrition and ODIN under grant agreements numbers 289346 and 613977.

**Disclosure summary**

RJM, SK, IS, RF, SVG, AC, SD, SC, AP, SMR, NJG, JWG, EMC have nothing to disclose. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. NJB reports remuneration from Internis Pharmaceuticals Ltd, outside the submitted work. ATP reports grants from Arthritis Research Council, during the conduct of the study. SJB works with a group who have received funding from the following companies from other work: Danone, Nestec, Abbott Nutrition. KMG reports reimbursement for speaking at Nestle Nutrition Institute conferences, grants from Abbott Nutrition & Nestec, outside the submitted work; in addition, KMG has a patent Phenotype Prediction pending, a patent Predictive Use of CpG Methylation pending, and a patent Maternal Nutrition Composition pending, not directly related to this work. HMI reports grants from Medical Research Council, Arthritis Research UK, European Union’s Seventh Framework Programme, during the conduct of the study; and while not directly receiving funding from other bodies, members of her team have received funding from the following companies from other work: Danone, Nestec, Abbott Nutrition. MKJ reports personal fees from Stirling Anglia, Consilient Health and Internis, outside the submitted work.

**Clinical Trial Registry number:** ISRCTN:82927713; EUDRACT:2007-001716-23

**Word count:** 3363

**Tables:** 3

**Figures:** 3

**Abstract**

**Context:** Single nucleotide polymorphisms (SNP) in genes related to vitamin D metabolism have been associated with serum 25-hydroxyvitamin D [25(OH)D] concentration, but these relationships have not been examined following antenatal cholecalciferol supplementation.

**Objective:** To determine whether SNPs in DHCR7, CYP2R1, CYP24A1 and GC are associated with the response to gestational cholecalciferol supplementation.

**Design:** Within-randomization-group analysis of the MAVIDOS trial of antenatal cholecalciferol supplementation.

**Setting:** Hospital antenatal clinics

**Participants:** 682 women of White ethnicity (351 placebo, 331 cholecalciferol) were included. SNPs at rs12785878 (DHCR7), rs10741657 (CYP2R1), rs6013897 (CYP24A1) and rs2282679 (GC) were genotyped

**Interventions:** 1000 IU/day cholecalciferol from 14 weeks gestation until delivery

**Main Outcome Measure:** 25(OH)D at randomisation and 34 weeks gestation were measured in a single batch (Diasorin Liaison). Associations between 25(OH)D and the SNPs were assessed by linear regression using an additive model (beta represents the change in 25(OH)D per additional common allele).

**Results**: Only rs12785878 (DHCR7) was associated with baseline 25(OH)D [β=3.1nmol/l (95% CI 1.0, 5.2), p<0.004]. In contrast, rs10741657 (CYP2R1) [β=-5.2nmol/l (95%CI -8.2, -2.2), p=0.001] and rs2282679 (GC) [β=4.2nmol/l (95%CI 0.9, 7.5), p=0.01] were associated with achieved 25(OH)D status following supplementation, while rs12785878 and rs6013897 (CYP24A1) were not.

**Conclusions:**  Genetic variation in DHCR7, which encodes 7-dehyrocholesterol reductase in the epidermal vitamin D biosynthesis pathway, appears to modify baseline 25(OH)D. In contrast, the response to antenatal cholecalciferol supplementation was associated with SNPs in CYP2R1, which may alter 25-hydroxylase activity, and GC, which may affect vitamin D binding protein synthesis or metabolite affinity.

**Precis**

Associations between SNPs in the vitamin D metabolism pathway and 25(OH)D were assessed before and after antenatal vitamin D supplementation. The associations differed at the two time points.

**Introduction**

Antenatal vitamin D supplementation is now recommended for all pregnant women in many national guidelines ([1-3](#_ENREF_1)) as severe maternal vitamin D deficiency can result in symptomatic neonatal hypocalcaemia ([4](#_ENREF_4)). Furthermore, associations between maternal vitamin D status and obstetric complications ([4](#_ENREF_4)) and offspring musculoskeletal development ([5-7](#_ENREF_5)) have been reported.

Risk factors for vitamin D deficiency, in addition to geographic and seasonal variation, are well established. These include ethnicity, extent of skin covering, liberal use of sun protection, adiposity and age. It is also increasingly recognised that genetic variation influences 25-hydroxyvitamin D [25(OH)D] status; In our previous genome wide association study (GWAS) we have demonstrated that a number of single nucleotide polymorphisms (SNP) in or near to genes encoding key components of the vitamin D metabolism pathway are associated with serum 25(OH)D level ([8](#_ENREF_8)). These include *DHCR7* encoding 7-dehydrocholesterol reductase, *CYP2R1* and *CYP24A1* encoding 25-hydroxylase and 24-hydroxylase, respectively, and *GC* encoding vitamin D binding protein (VDP). Several of these SNPs have been associated with the serum 25(OH)D increase in response to vitamin D supplementation in small studies ([9-11](#_ENREF_9)).

Pregnancy is a physiologically unique period, involving haemodilution and hormonal and metabolic changes. For example, VDP rises early in pregnancy, and 1,25-dihydroxyvitamin D increases during the second and third trimesters ([12](#_ENREF_12)). Supplementation with cholecalciferol increases maternal serum 25(OH)D concentration ([7](#_ENREF_7)), and we have previously demonstrated that the 25(OH)D achieved in response to supplementation in pregnancy is associated with pregnancy weight gain, compliance and baseline 25(OH)D ([13](#_ENREF_13)). In our previous study, in contrast to data from non-pregnant adults, baseline body mass index (BMI), measures of adiposity and maternal age were not associated with response to cholecalciferol supplementation in pregnancy ([13](#_ENREF_13)). Considering this, and the physiological changes to the vitamin D pathway in pregnancy, it is therefore possible that the genetic variants associated with baseline serum 25(OH)D status and the response to supplementation also differ between the pregnant and non-pregnant state. We therefore undertook this study to determine whether SNPs within the vitamin D metabolism pathway known to modify vitamin D status are also associated with the response to antenatal vitamin D supplementation.

**Materials and Methods**

*The Maternal Vitamin D Osteoporosis Study (MAVIDOS)*

The MAVIDOS study is a multicentre, double-blind, randomised, placebo-controlled trial of vitamin D supplementation in pregnancy. The primary outcome was neonatal bone mass. A detailed description of the study methods ([14](#_ENREF_14)) and primary findings have been published previously ([7](#_ENREF_7)). The study was approved by the Southampton and South West Hampshire Research Ethics Committee. MAVIDOS was registered prospectively (ISRCTN:82927713; EUDRACT:2007-001716-23); full approval from UK MHRA was granted, and written, informed consent was obtained from all participants.

Briefly, women attending one of three United Kingdom (UK) hospitals [University Hospital Southampton NHS Foundation Trust, Southampton, UK (latitude 50.9° North); Oxford University Hospitals NHS Foundation Trust, Oxford, UK (latitude 51.8° North); Sheffield Hospitals NHS Trust (University of Sheffield), Sheffield, UK (latitude 53.4° North)] for early pregnancy ultrasound screening (11-14 weeks’ gestation) between 6th October 2008 and 11th February 2014 were invited to participate in the study. Inclusion criteria were: age over 18 years, singleton pregnancy, and gestation less than 17 weeks based on last menstrual period and ultrasound measurements. Women with known metabolic bone disease, renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to interfere with fetal growth, fetal anomalies on ultrasonography and women already using >400IU/day vitamin D supplementation were excluded. A screening blood sample was obtained and analysed on the local NHS platform [all three laboratories (Southampton, Oxford and Sheffield) participate in DEQAS vitamin D quality assurance system (http://www.deqas.org/)]. Women with 25(OH)D between 25 and 100nmol/l and serum calcium <2.75mmol/l were eligible to enrol fully in the study.

Participants were randomised to either cholecalciferol 1000IU/day or matched placebo [Merck KGaA, (Darmstadt, Germany)/ Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare)], which was commenced before 17 weeks’ gestation. Packs of study treatment were randomly assigned in a 1:1 ratio by Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare) by a computer-generated sequence in randomly permuted blocks of ten, starting randomly midway through the block, and sequentially numbered, before delivery to the study sites, and then dispensed in order by each study pharmacist. The study medication was provided in a blister pack in a single box containing all medication for the whole pregnancy. The participants, individuals providing antenatal and intrapartum care, and all field researchers involved in data collection and sample analysis are blinded to the assignment to the intervention. All participants received standard antenatal care, and could continue self-administration of dietary supplements containing up to 400IU/day vitamin D.

*Maternal assessments during pregnancy*

Prior to commencing the study medication, and again at 34 weeks’ gestation, the women attended the research centre for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment) and health (past medical history, current medication use) using interviewer-led questionnaires. Ethnicity was reported by the participant and subsequently categorized as White or non-White.

Anthropometric measurements included height, measured to the nearest 0.1cm using a stadiometer, and weight, assessed to the nearest 0.1kg using calibrated electronic scales. Pregnancy weight gain was calculated as the difference between the weights at commencing the study medication and at 34 weeks’ of gestation.

Compliance with study medication was assessed by asking participants to bring any remaining study medication to each assessment. The pills were counted and compliance calculated as the number consumed divided by the expected consumption based on the number of days since the medication was dispensed and expressed as a percentage.

*Assessment of 25(OH)D*

On the day that the study medication was dispensed and at 34 weeks’ gestation, a non-fasted venous blood sample was obtained, and serum stored at -80°C. 25(OH)D concentration was assessed by chemiluminescence immunoassay (Liaison automated platform, Diasorin, Minnesota, USA). All samples were analysed in a single batch at the end of the study at MRC Human Nutrition Research, Cambridge, UK. Details of assay performance and quality control through participation in DEQAS, NIST and NEQAS are given elsewhere ([15](#_ENREF_15),[16](#_ENREF_16)).

*Analysis of SNPs*

Genotyping was undertaken by LGC Genomics (Hoddeston, UK) using KASP™ competitive allele-specific PCR. SNPs selected for analysis were based on the findings of a previous GWAS ([8](#_ENREF_8)). These were rs12785878 (*DHCR7*), rs10741657 (*CYP2R1*), rs6013897 (*CYP24A1*), rs2282679 (*GC*).

*Statistical Analysis*

Women who had a measurement of 25(OH)D at both 14 and 34 weeks’ gestation, had genetic analysis and delivered a liveborn infant were included in the analysis. The SNPs included in this analysis were chosen based on findings in the previous GWAS, which included only individuals of European ancestry ([8](#_ENREF_8)). We therefore limited our study population to only women of White ethnicity (95.8% of eligible women).

 All outcomes were assessed for normality using visual inspection. Serum 25(OH)D concentrations at 14 and at 34 weeks’ gestation were normally distributed. Characteristics of the women in the two treatment arms were compared using t-test, Mann-Whitney U and χ2 test for normally distributed, non-normally distributed and categorical variables, respectively. All participants were analysed in the group to which they were originally randomised.

Linear regression was used to examine the association between the 4 SNPs and the outcomes using an additive model with the homozygous low frequency allele (for this cohort) as the reference group. The additive model thus expresses the change in outcome per additional common allele. The outcomes assessed were 25(OH)D at 14 weeks’ gestation in all study participants and the achieved 25(OH)D at 34 weeks’ gestation in the participants randomised to cholecalciferol. Additionally in women randomised to cholecalciferol we assessed the relationship between the SNPs and the change in vitamin D using the residuals of 25(OH)D at 34 weeks’ gestation regressed on 25(OH)D at 14 weeks’ gestation as the outcome. Multivariate linear regression was then used in order to adjust for relevant confounders. Maternal age, BMI, physical activity and smoking status at 14 weeks’ gestation, educational attainment, and season of blood measurement were included in the model for baseline 25(OH)D as these have previously been shown to be associated with serum 25(OH)D status in pregnancy ([17-21](#_ENREF_17)). For the models for the 25(OH)D achieved at 34 weeks’ gestation compliance with study medication, baseline 25(OH)D and pregnancy weight gain (instead of BMI) were additionally included as we have previously demonstrated in this cohort of women that these factors are associated with the response to cholecalciferol supplementation ([13](#_ENREF_13)). Seasons were defined according to the UK Meteorological office recommendations (www.metoffice.gov.uk) with winter (December-February); spring (March-May); summer (June-August); and autumn (September-November). As four SNPs were assessed, additionally, a Bonferroni correction was used to account for multiple testing. We additionally undertook sensitivity analysis in which women who reported having taken any additional vitamin D containing supplements within 90 days of the late pregnancy blood sampling were excluded.

Finally, to determine the combined effects of SNPs, a genotype risk score (GRS) was calculated as the sum of the number of risk alleles at rs10741657 (G) and rs2282679 (C), as identified in the previous analysis. The GRS score ranged from 0-4, with a score of 0 representing no risk alleles. Multivariate linear regression was used to determine the association of GRS with 25(OH)D, using the same confounding factors as before.

All analyses were performed in Stata v14.2 (Statacorp, College Station, Texas, USA). A p value of <0.05 was considered statistically significant.

**Results**

682 women were included in the analysis (**Figure 1**). Women who delivered a liveborn infant but who were not included in this analysis due to missing 25(OH)D or genetic analysis were of similar age, smoking status and BMI to those included in the analysis (p>0.05 for all). Baseline characteristics of the women randomised to placebo and cholecalciferol were similar (**Table 1**). The distributions of alleles within the SNPs of interest were also similar between the two groups (Table 1).

25(OH)D was similar at baseline between the two groups, but significantly higher in the women randomised to cholecalciferol at 34 weeks gestation [mean 67.3nmol/l (SD 20.8nmol/l)] compared to placebo [mean 43.0nmol/l (SD 22.2nmol/l), p<0.001].

*3.1 Associations with baseline 25(OH)D*

Amongst all 682 women, the common allele (T) of rs12785878 (*DHCR7*) was associated with greater baseline serum 25(OH)D concentration (**Table 2**). This association persisted in multivariate analysis adjusting for maternal age, BMI, smoking status, physical activity, educational achievement and season of blood sampling [β=3.1 nmol/l per T allele (95%CI 1.0, 5.2), p=0.016]. There were no significant associations between the SNPs at rs10741657 (*CYP2R1*), rs6013897 (*CYP24A1*) and rs2282679 (*GC*) and baseline 25(OH)D in the fully adjusted model (Table 2).

*3.2 Associations with 25(OH)D following supplementation*

In women who were randomised to cholecalciferol supplements, the common G allele of rs10741657 (*CYP2R1*) was associated with lower serum 25(OH)D concentration at 34 weeks’ gestation, whereas the common A allele of rs2282679 (*GC*) was associated with greater 34 week serum 25(OH)D (**Table 3**). These associations persisted after adjustment for potential confounding factors (Maternal age, physical activity and smoking status at 14 weeks’ gestation, educational attainment, and season of blood measurement, compliance with study medication, baseline 25(OH)D and pregnancy weight gain). There were no significant associations between the SNPs at rs12785878 (*DHCR7*) and rs6013897 (*CYP24A1*) and 25(OH)D at 34 weeks’ gestation (Table 3). When both rs10741657 (*CYP2R1*) [β=-5.0 nmol/l per G allele (95% CI -8.0, -1.9), p=0.001] and rs2282679 (*GC*) [β=3.8 nmol/l per A allele (95% CI 0.6, 7.1), p=0.021] were included simultaneously in a regression model with confounders the effect sizes were maintained. Furthermore a GRS including rs10741657 and rs2282679 showed that for each additional risk allele, late pregnancy serum 25(OH)D concentration after supplementation with cholecalciferol was lower by 4.4 nmol/l (95% CI 2.3, 6.6 nmol/l, p<0.001). This association between the GRS and 25(OH)D was not present pre-supplementation in early pregnancy (**Figure 2**).

Similarly, rs10741657 (*CYP2R1*) and rs2282679 (*GC*) were associated with the change in 25(OH)D from 14 to 34 weeks gestation in women who received the cholecalciferol supplement, while rs12785878 (*DHCR7*) and rs6013897 (*CYP24A1*) were not (**Figure 3**). The GRS was also negatively associated with the change in serum 25(OH)D concentration (β=-4.4 nmol/l per risk allele [95% CI -6.6,-2.3], p<0.001], such that women who had more risk alleles had a smaller increment in 25(OH)D.

*3.3 Sensitivity analysis*

As the women were allowed to continuing taking vitamin D supplements containing up to 400IU/day, in sensitivity analyses we included only women who were not taking additional vitamin D containing supplements at 34 weeks gestation (n=224, 67.7%). The relationships were similar to those in the whole cohort.

**Discussion**

This study assessed the relationships between common genetic variants and the response to vitamin D supplementation in pregnancy; rs12785878 in *DHCR7* was associated with 25(OH)D status in early pregnancy prior to vitamin D supplementation, whereas rs10741657 in *CYP2R1* and rs2282679 in *GC* were associated with both the achieved and change in 25(OH)D concentration following supplementation with 1000IU/day cholecalciferol.

GWAS has previously been used to identify SNPs associated with serum 25(OH)D status ([8](#_ENREF_8),[22](#_ENREF_22)). However, there are few studies investigating whether common genetic variants modify the response to supplementation, and to our knowledge, no previous studies in pregnant women. Two previous studies in non-pregnant adults similarly found that rs2282679 (*GC*) and rs10741567 (*CYP2R1*) are associated with serum 25(OH)D increment in response to supplementation ([10](#_ENREF_10),[11](#_ENREF_11)), whereas Barry et al did not identify these associations ([9](#_ENREF_9)). The observed difference in achieved 25(OH)D between the homozygous gene variants were higher in the studies of Sollid et al ([10](#_ENREF_10)) and Didriksen et al ([11](#_ENREF_11)) (15-18nmol/l) than our cohort (9-10nmol/l), but this could reflect the higher cholecalciferol doses used in those studies and/or alterations in vitamin D metabolism and volume of distribution in pregnancy.

In our population the SNPs associated with baseline 25(OH)D differed to those associated with the response to cholecalciferol supplementation. The published GWAS ([8](#_ENREF_8),[22](#_ENREF_22)) did not stratify individuals by vitamin D supplement usage, which could account for differing associations before and after supplementation in our cohort, or the differing findings might reflect the lower power in our study. Nonetheless, although the functional consequences of these genetic markers remain the subject of research, these differences are biologically plausible. The *DHCR7* gene encodes dehydrocholesterol reductase which converts 7-dehydrocholesterol (7-DHC) back to cholesterol, thereby reducing the availability of 7-DHC for conversion to previtamin D. The association of this SNP with only baseline 25(OH)D is biologically consistent with the notion that the relative proportion of 25(OH)D obtained from vitamin D biosynthesis in the skin as opposed to dietary intake is lower following supplementation.

*CYP2R1* encodes a 25-hydroxylase, a key enzyme involved in the conversion of vitamin D to 25(OH)D ([23](#_ENREF_23)). Hepatic hydroxylation of pre-vitamin D to 25(OH)D is thought not to be regulated and is therefore primarily dependent on availability of the substrate. We found that the rs10741657 SNP was not associated with baseline 25(OH)D, but was associated with the response to gestational vitamin D supplementation, therefore suggesting that this SNP only modifies 25(OH)D status when the substrate is more readily available and that at the baseline measurement saturation of the enzyme had not been reached. rs10741657 is located with the promoter region of the *CYP2R1* gene, and our findings would suggest that presence of the A allele increases enzyme production. As the G allele at rs10741657, which was more frequent in our population, was associated with lower 25(OH)D following supplementation, it could be postulated that this allele previously conferred an evolutionary advantage to prevent vitamin D toxicity.

In addition to associations with 25(OH)D, rs2282679 in *GC* has also previously been associated with serum VDP concentrations, with carriers of the low frequency C allele having reduced concentrations of VDP and 25(OH)D ([8](#_ENREF_8)). SNPs in *GC* have also been associated with the binding affinities of 25(OH)D to VDP ([24](#_ENREF_24)), although the effect of rs2282679 on binding affinity has not been established. We similarly found that the C allele was associated with lower achieved 25(OH)D following antenatal vitamin D supplementation. Unfortunately analysis of VDP was not available in this cohort of women.

It is well recognised that individuals with darker skin pigmentation living at higher latitudes tend to have lower 25(OH)D. This may in part reflect clustering of genotypes within ethnic groups. For example, the G allele at rs12785878 (DHCR7) is typically more prevalent in non-White populations ([25-29](#_ENREF_25)). Although our study included only women of White ethnicity, the G allele was associated with lower baseline 25(OH)D. The greater prevalence of the G allele at rs12785878 with a resulting increase in 7-DHCR activity (either due to a functional modification or increased synthesis) leading to reduced availability of 7-DHC for conversion to pre-vitamin D might contribute to lower 25(OH)D in individuals with darker skin pigmentation. Furthermore, it has previously been shown that the rs2282679 (GC) was only significantly associated with 25(OH)D in European Americans and not African Americans ([30](#_ENREF_30)), suggesting further ethnicity specific associations, which might form the basis of future study, and consideration in clinical approaches to supplementation.

There are a number of limitations to our findings. Firstly, due to stipulations made during the ethics approval process, we were unable to include participants with a baseline 25(OH)D less than 25nmol/l or greater than 100nmol/l. As such, confirmation of these findings in severely vitamin D deficient women is needed as it is possible that women with specific genotypes were selectively excluded by this inclusion criterion. Secondly, we did not identify associations between several SNPs and either baseline and/or achieved 25(OH)D that had previously been associated with 25(OH)D in GWAS ([8](#_ENREF_8),[22](#_ENREF_22)). This may reflect the lower power of this study, although our findings are similar to other small studies ([10](#_ENREF_10),[11](#_ENREF_11)). Furthermore, in this study we performed analysis only of candidate SNPs previously identified to be associated with differences in 25(OH)D status. However, it is possible that alternate SNPs/genes that are not clinically important to 25(OH)D level in non-pregnant adults would be significant in pregnant women and could be identified by GWAS.

In conclusion, common genetic variation is associated with baseline 25(OH)D in pregnancy and the response to antenatal supplementation with 1000IU/day cholecalciferol, but with differing SNPs appearing to be important before and after supplementation. Our findings suggest that analysis of SNPs may have an important role in identifying high risk categories of individuals who are likely to require higher doses of vitamin D to achieve repletion, and studies are needed to establish clinical approaches to vitamin D supplementation that are centred on individual characteristics.

**Acknowledgements**

This work was supported by grants from the Arthritis Research UK (17702), Medical Research Council (4050502589), Bupa Foundation, National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, and NIHR Musculoskeletal Biomedical Research Unit, University of Oxford. IS and AP were funded by the Medical Research Council (MRC) (programme code U105960371). The work leading to these results was supported by the European Union's Seventh Framework Programme (FP7/2007-2013), projects EarlyNutrition and ODIN under grant agreements numbers 289346 and 613977. RJM, NCH and CC are joint first author. We are extremely grateful to Merck GmbH for the kind provision of the Vigantoletten supplement. Merck GmbH had no role in the trial execution, data collection, analysis or manuscript preparation. The authors had full access to all study data.

**Author Contributions**

NCH, CC, SMR, SJB, KMG, NJB, SK, ATP, IS, AP, HMI and MKJ designed the research; NCH, CC, NJB, RF, DVG, SK, ATP, MKJ, NJG and JWH and the MAVIDOS trial group conducted the research; SD, RJM, SJB and SRC performed the statistical analysis; RJM, NCH, CC and EMC wrote the paper; CC had primary responsibility for the final content. All authors have read and approved the final manuscript.

**References**

**1.** National Institute for Health and Clinical Excellence. Antenatal care (NICE Clinical Guideline 62). [www.guidance.nice.org.uk/cg622010](http://www.guidance.nice.org.uk/cg622010).

**2.** Paxton GA, Teale GR, Nowson CA, Mason RS, McGrath JJ, Thompson MJ, Siafarikas A, Rodda CP, Munns CF. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. The Medical journal of Australia2013; 198:142-143

**3.** Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism2011; 96:1911-1930

**4.** Harvey NC, Holroyd C, Ntani G, Javaid K, Cooper P, Moon R, Cole Z, Tinati T, Godfrey K, Dennison E, Bishop NJ, Baird J, Cooper C. Vitamin D supplementation in pregnancy: a systematic review. Health technology assessment (Winchester, England)2014; 18:1-190

**5.** Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, Arden NK, Godfrey KM, Cooper C. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet2006; 367:36-43

**6.** Harvey NC, Moon RJ, Sayer AA, Ntani G, Davies JH, Javaid MK, Robinson SM, Godfrey KM, Inskip HM, Cooper C, Group TSWsSS. Maternal antenatal vitamin D status and offspring muscle development: findings from the Southampton Women’s Survey. The Journal of clinical endocrinology and metabolism2014; 99:330-337

**7.** Cooper C, Harvey NC, Bishop NJ, Kennedy S, Papageorghiou AT, Schoenmakers I, Fraser R, Gandhi SV, Carr A, D'Angelo S, Crozier SR, Moon RJ, Arden NK, Dennison EM, Godfrey KM, Inskip HM, Prentice A, Mughal MZ, Eastell R, Reid DM, Javaid MK. Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. The lancet Diabetes & endocrinology2016; 4:393-402

**8.** Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Jarvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hypponen E, Spector TD. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (London, England)2010; 376:180-188

**9.** Barry EL, Rees JR, Peacock JL, Mott LA, Amos CI, Bostick RM, Figueiredo JC, Ahnen DJ, Bresalier RS, Burke CA, Baron JA. Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. The Journal of clinical endocrinology and metabolism2014; 99:E2133-2137

**10.** Sollid ST, Hutchinson MY, Fuskevag OM, Joakimsen RM, Jorde R. Large Individual Differences in Serum 25-Hydroxyvitamin D Response to Vitamin D Supplementation: Effects of Genetic Factors, Body Mass Index, and Baseline Concentration. Results from a Randomized Controlled Trial. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2016; 48:27-34

**11.** Didriksen A, Grimnes G, Hutchinson MS, Kjaergaard M, Svartberg J, Joakimsen RM, Jorde R. The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. European journal of endocrinology / European Federation of Endocrine Societies2013; 169:559-567

**12.** Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. The Journal of clinical investigation1981; 67:589-596

**13.** Moon RJ, Harvey NC, Cooper C, D'Angelo S, Crozier SR, Inskip HM, Schoenmakers I, Prentice A, Arden NK, Bishop NJ, Carr A, Dennison EM, Eastell R, Fraser R, Gandhi SV, Godfrey KM, Kennedy S, Mughal MZ, Papageorghiou AT, Reid DM, Robinson SM, Javaid MK. Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy. J Clin Endocrinol Metab2016:jc20162869

**14.** Harvey NC, Javaid K, Bishop N, Kennedy S, Papageorghiou AT, Fraser R, Gandhi SV, Schoenmakers I, Prentice A, Cooper C. MAVIDOS Maternal Vitamin D Osteoporosis Study: study protocol for a randomized controlled trial. The MAVIDOS Study Group. Trials2012; 13:13

**15.** Jones KS, Assar S, Harnpanich D, Bouillon R, Lambrechts D, Prentice A, Schoenmakers I. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab2014; 99:3373-3381

**16.** Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl2012; 243:32-40

**17.** Moon RJ, Crozier SR, Dennison EM, Davies JH, Robinson SM, Inskip HM, Godfrey KM, Cooper C, Harvey NC. Tracking of 25-hydroxyvitamin D status during pregnancy: the importance of vitamin D supplementation. Am J Clin Nutr2015; 102:1081-1087

**18.** Crozier SR, Harvey NC, Inskip HM, Godfrey KM, Cooper C, Robinson SM. Maternal vitamin D status in pregnancy is associated with adiposity in the offspring: findings from the Southampton Women's Survey. The American journal of clinical nutrition2012; 96:57-63

**19.** Xiao JP, Zang J, Pei JJ, Xu F, Zhu Y, Liao XP. Low maternal vitamin D status during the second trimester of pregnancy: a cross-sectional study in Wuxi, China. PloS one2015; 10:e0117748

**20.** Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R. High prevalence of vitamin D deficiency in pregnant women: a national cross-sectional survey. PloS one2012; 7:e43868

**21.** Schneuer FJ, Roberts CL, Guilbert C, Simpson JM, Algert CS, Khambalia AZ, Tasevski V, Ashton AW, Morris JM, Nassar N. Effects of maternal serum 25-hydroxyvitamin D concentrations in the first trimester on subsequent pregnancy outcomes in an Australian population. The American journal of clinical nutrition2014; 99:287-295

**22.** Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D. Genome-wide association study of circulating vitamin D levels. Human molecular genetics2010; 19:2739-2745

**23.** Miller WL. Genetic disorders of Vitamin D biosynthesis and degradation. The Journal of steroid biochemistry and molecular biology2016;

**24.** Braithwaite VS, Jones KS, Schoenmakers I, Silver M, Prentice A, Hennig BJ. Vitamin D binding protein genotype is associated with plasma 25OHD concentration in West African children. Bone2015; 74:166-170

**25.** Xu X, Mao J, Zhang M, Liu H, Li H, Lei H, Han L, Gao M. Vitamin D Deficiency in Uygurs and Kazaks Is Associated with Polymorphisms in CYP2R1 and DHCR7/NADSYN1 Genes. Medical science monitor : international medical journal of experimental and clinical research2015; 21:1960-1968

**26.** Elkum N, Alkayal F, Noronha F, Ali MM, Melhem M, Al-Arouj M, Bennakhi A, Behbehani K, Alsmadi O, Abubaker J. Vitamin D insufficiency in Arabs and South Asians positively associates with polymorphisms in GC and CYP2R1 genes. PloS one2014; 9:e113102

**27.** Ryan LM, Chamberlain JM, Singer SA, Wood R, Tosi LL, Freishtat RJ, Gordish-Dressman H, Teach SJ, Devaney JM. Genetic influences on vitamin D status and forearm fracture risk in African American children. Journal of investigative medicine : the official publication of the American Federation for Clinical Research2012; 60:902-906

**28.** Grunhage F, Hochrath K, Krawczyk M, Hoblinger A, Obermayer-Pietsch B, Geisel J, Trauner M, Sauerbruch T, Lammert F. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology (Baltimore, Md)2012; 56:1883-1891

**29.** Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, Greissl C, Ramos-Lopez E, Hypponen E, Dunger DB, Spector TD, Ouwehand WH, Wang TJ, Badenhoop K, Todd JA. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes2011; 60:1624-1631

**30.** Batai K, Murphy AB, Shah E, Ruden M, Newsome J, Agate S, Dixon MA, Chen HY, Deane LA, Hollowell CM, Ahaghotu C, Kittles RA. Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Human genetics2014; 133:1395-1405

**Table and Figure Legends**

**Table 1: Characteristics of women included in the analysis**

**Table 2: Association of SNPs with baseline 25(OH)D in early pregnancy.** The homozygous low frequency gene variant was used as the reference group, and beta represents the change in 25(OH)D (nmol/l) per common allele.

**Table 3: Association of SNPs with achieved 25(OH)D at 34 weeks gestation following supplementation with 1000 iu/day cholecalciferol in pregnancy.** The homozygous low frequency gene variant was used as the reference group. Beta represents the effect on achieved 25(OH)D (nmol/l) per common allele.

**Figure 1:** Consort diagram

**Figure 2:** 25(OH)D before and after supplementation with cholecalciferol in pregnancy according to genotype risk score for the SNPs rs10741657 (*CYP2R1*) and rs2282679 (*GC*). Shown as mean and 95% confidence interval for each group. P is for trend by linear regression with adjustment for confounders.

**Figure 3**: Associations between SNPs and change in 25(OH)D from 14 to 34 weeks gestation following supplementation with 1000 IU/day cholecalciferol. Shown as beta and 95% confidence interval. The homozygous low frequency allele was used as the reference group, with the beta representing the change in 25(OH)D (nmol/l) per common allele (additive model). Models were adjusted for age, physical activity, smoking status, educational attainment, season of blood sampling, compliance, and pregnancy weight gain.

**Table 1: Characteristics of women included in the analysis**

|  |  |  |
| --- | --- | --- |
|  | **Placebo** | **Cholecalciferol 1000 iu/day** |
| n | 351 | 331 |
| Age (years), mean (SD) | 30.8 (5.4) | 30.8 (5.0) |
| Current smoking, n (%) | 29 (8.3) | 24 (7.3) |
| Educational attainment ≥ A level (high school), n (%) | 258 (74.4) | 264 (80.0) |
| BMI (kg/m2), median (IQR) | 25.5 (23.0-29.7) | 24.7 (22.3-29.3) |
| Pregnancy weight gain (kg), mean (SD) | 9.5 (3.6) | 9.5 (3.4) |
| Strenuous exercise ≥ once per week, n (%) | 45 (13.8) | 50 (16.2) |
| 25(OH)D at 14 weeks (nmol/l), mean (SD) | 45.4 (16.5) | 46.1 (17.0) |
| rs12785878 (*DHCR7*), n(%) |  |  |
|  | G:G | 17 (4.8) | 14 (4.3) |
|  | T:G | 114 (32.5) | 120 (36.6) |
|  | T:T | 220 (62.7) | 194 (59.1) |
| rs10741657 (*CYP2R1*), n (%) |  |  |
|  | A:A | 57 (16.6) | 51 (15.5) |
|  | G:A | 156 (45.3) | 148 (45.1) |
|  | G:G | 131 (38.1) | 129 (39.3) |
| rs6013897 (*CYP24A1*), n (%) |  |  |
|  | A:A | 10 (2.9) | 15 (4.6) |
|  | T:A | 126 (36.5) | 102 (31.4) |
|  | T:T | 209 (60.6) | 208 (64.0) |
| rs2282679 (*GC*), n (%) |  |  |
|  | C:C | 37 (10.6) | 34 (10.3) |
|  | C:A | 149 (42.6) | 136 (41.3) |
|   | A:A | 164 (46.9) | 159 (48.3) |

**Table 2: Association of SNPs with baseline 25(OH)D in early pregnancy.** The homozygous low frequency gene variant was used as the reference group, and beta represents the change in 25(OH)D (nmol/l) per common allele.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SNP** | **Reference****Allele** | **Common allele** | **Univariate** | **Adjusted 1** |  |
|  | **n** | **β****(95%CI)** | **p** | **n** | **β (95%CI)** | **p** | **Corrected p 2**  |
| **rs12785878** (*DHCR7*) | G | T | 679 | 3.7(1.5, 5.8) | 0.001 | 622 | 3.1 (1.0, 5.2) | 0.004 | 0.012 |
| **rs10741657** (*CYP2R1*) | A | G | 672 | -1.1(-2.9,0.7) | 0.24 | 616 | -1.4 (-3.2, 0.4) | 0.12 | 0.47 |
| **rs6013897** (*CYP24A1*) | A | T | 670 | 1.2(-1.1, 3.4) | 0.31 | 613 | 0.8 (-1.4, 3.0) | 0.46 | 1.0 |
| **rs2282679** (*GC*) | C | A | 679 | 2.2(0.3, 4.1) | 0.02 | 622 | 1.7(-0.2, 3.5) | 0.08 | 0.31 |

1Adjusted for age, BMI, smoking status (yes/no), physical activity (Strenuous activity more than once per week, yes/no), educational achievement (A levels or higher, yes/no), season of blood sampling (winter, spring, summer, autumn).

2Bonferroni corrected p-values

**Table 3: Association of SNPs with achieved 25(OH)D at 34 weeks gestation following supplementation with 1000 iu/day cholecalciferol in pregnancy.** The homozygous low frequency gene variant was used as the reference group. Beta represents the effect on achieved 25(OH)D (nmol/l) per common allele.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SNP** | **Reference****Allele** | **Common allele** | **Univariate** | **Adjusted 1** |  |
|  | **n** | **β****(95%CI)** | **p** | **n** | **β (95%CI)** | **p** | **Corrected p 2** |
| **rs12785878** (*DHCR7*) | G | T | 328 | 2.6 (-1.4, 6.5) | 0.20 | 304 | 0.3 (-3.5, 4.0) | 0.89 | 1.0 |
| **rs10741657** (*CYP2R1*) | A | G | 328 | -4.8 (-8.0, -1.6) | 0.004 | 304 | -5.2 (-8.2, -2.2) | 0.001 | 0.004 |
| **rs6013897** (*CYP24A1*) | A | T | 325 | -3.2 (-7.1, 0.8) | 0.11 | 301 | -1.0 (-4.8, 2.8) | 0.60 | 1.0 |
| **rs2282679** (*GC*) | C | A | 329 | 4.3 (0.9, 7.7) | 0.01 | 305 | 4.2 (0.9, 7.5) | 0.01 | 0.04 |

1Adjusted for age, pregnancy weight gain, smoking status (yes/no), physical activity (Strenuous activity more than once per week, yes/no), educational achievement (A levels or higher, yes/no), season of blood sampling (winter, spring, summer, autumn), compliance with study protocol and baseline 25(OH)D

2Bonferroni corrected p-values

**Figure 1:** Consort diagram



**Figure 2:** 25(OH)D before and after supplementation with cholecalciferol in pregnancy according to genotype risk score for the SNPs rs10741657 (*CYP2R1*) and rs2282679 (*GC*). Shown as mean and 95% confidence interval for each group. P is for trend by linear regression with adjustment for confounders.



**Figure 3**: Associations between SNPs and change in 25(OH)D from 14 to 34 weeks gestation following supplementation with 1000 IU/day cholecalciferol. Shown as beta and 95% confidence interval. The homozygous low frequency allele was used as the reference group, with the beta representing the change in 25(OH)D (nmol/l) per common allele (additive model). Models were adjusted for age, physical activity, smoking status, educational attainment, season of blood sampling, compliance, and pregnancy weight gain.

